ArticleJournal of general internal medicine2026
Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at Risk for Advanced Fibrosis in a Real-World Primary Care Setting: A Cross-Sectional Study.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundRecent guidelines provide recommendations for diagnosing metabolic dysfunction-associate steatotic liver disease (MASLD) when hepatic steatosis is seen radiographically, but questions remain as to when to pursue imaging for the evidence of hepatic steatosis.
objectiveWe aimed to test the performance of traditional MASLD case-finding cues for detecting MASLD at-risk for advanced fibrosis.
designWe performed a cross-sectional study of electronic health record data from a large primary care clinic between 2012 and 2021. PATIENTS: Patients with abdominal imaging and inputs for Fibrosis-4 Index (FIB-4) calculation. MAIN MEASURES: We examined the performance characteristics of type 2 diabetes mellitus (T2DM), a BMI ≥ 30 kg/m KEY
resultsThe sample included 9000 patients of whom 1683 (19%) patients had MASLD and 696 (8%) had MASLD and an indeterminate-risk or greater for advanced fibrosis. T2DM, BMI ≥ 30 kg/m
conclusionsWhile historical cues for MASLD case finding had low sensitivities individually, the union of these three, simple, broadly available signals had a high sensitivity for MASLD at-risk for advanced fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.